Literature DB >> 6312869

Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency.

S DiMauro, J F Nicholson, A P Hays, A B Eastwood, A Papadimitriou, R Koenigsberger, D C DeVivo.   

Abstract

A 2-week-old boy had profound generalized weakness, hypotonia, hyporeflexia, macroglossia, and severe lactic acidosis. The infant improved spontaneously: he held his head at 4 1/2 months, rolled over at 7 months, and walked by 16 months. At 33 months of age, he had mild proximal weakness. Macroglossia disappeared by age 4 months. Blood lactic acid declined steadily and was normal by 14 months of age. Histochemical and ultrastructural studies of muscle biopsy specimens obtained at 1 and 7 months of age showed excessive mitochondria, lipid, and glycogen; a third biopsy at age 36 months showed only atrophy of scattered fibers. Cytochrome c oxidase stain was positive in fewer than 5% of fibers in the first biopsy, in approximately 60% of fibers in the second biopsy, and in all fibers in the third biopsy. Biochemical analysis showed an isolated defect of cytochrome c oxidase activity, which was only 8% of the lowest control level in the first biopsy; the activity increased to 47% in the second biopsy and was higher than normal in the third. In contrast to that in the fatal infantile form of cytochrome c oxidase deficiency, the enzyme defect in this condition is reversible. The biochemical basis for this difference remains to be explained.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312869     DOI: 10.1002/ana.410140209

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

1.  Mitochondrial phosphoenolpyruvate carboxykinase deficiency.

Authors:  J V Leonard; K Hyland; N Furukawa; P T Clayton
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

Review 2.  Mitochondrial myopathies.

Authors:  S DiMauro; E Bonilla; M Zeviani; S Servidei; D C DeVivo; E A Schon
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

3.  Abnormal kinetic behavior of cytochrome oxidase in a case of Leigh disease.

Authors:  M Glerum; B H Robinson; C Spratt; J Wilson; D Patrick
Journal:  Am J Hum Genet       Date:  1987-10       Impact factor: 11.025

4.  Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder.

Authors:  A Bardosi; W Creutzfeldt; S DiMauro; K Felgenhauer; R L Friede; H H Goebel; A Kohlschütter; G Mayer; G Rahlf; S Servidei
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

Review 5.  The clinical maze of mitochondrial neurology.

Authors:  Salvatore DiMauro; Eric A Schon; Valerio Carelli; Michio Hirano
Journal:  Nat Rev Neurol       Date:  2013-07-09       Impact factor: 42.937

6.  Mitochondrial genome: defects, disease, and evolution.

Authors:  A Clarke
Journal:  J Med Genet       Date:  1990-07       Impact factor: 6.318

7.  Cytochrome c oxidase and coenzyme Q in neuromuscular diseases: a histochemical study.

Authors:  C Doriguzzi; L Palmucci; B Pollo; T Mongini; M Maniscalco; L Chiadò-Piat; D Schiffer
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  Benign mitochondrial encephalomyopathy in a patient with complex I deficiency.

Authors:  J M Trijbels; W Ruitenbeek; R C Sengers; A J Janssen; B A van Oost
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

9.  Progressive generalized brain atrophy and infantile spasms associated with cytochrome c oxidase deficiency.

Authors:  H D Bakker; C Van den Bogert; J G Drewes; P G Barth; H R Scholte; R J Wanders; W Ruitenbeek
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

10.  Pyruvate dehydrogenase activity is not deficient in the brain of three autopsied cases with Leigh disease (subacute necrotizing encephalomyelopathy, SNE).

Authors:  B Kustermann-Kuhn; K Harzer; R Schröder; W Permanetter; J Peiffer
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.